Pilot Neurobehavioral Therapy for Functional Neurological Disorder
Launched by RHODE ISLAND HOSPITAL · Mar 7, 2025
Trial Information
Current as of April 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is researching a treatment called Neurobehavioral Therapy (NBT) for people diagnosed with Motor Functional Neurological Disorder (mFND). The goal is to see if NBT can help improve the quality of life and reduce symptoms for those with this condition. The study will involve 40 participants, who will be divided into two groups: one group will receive NBT over 12 to 18 weeks, while the other group will continue with their standard medical care. Throughout the study, all participants will attend five clinic visits over one year to answer questions and complete surveys about their health and symptoms.
To be eligible for this trial, participants should be between 18 and 70 years old and have been diagnosed with mFND, experiencing at least one symptom in the past year. However, individuals with certain conditions, such as severe mental health issues, serious illnesses, or those currently engaged in other treatments for mFND, will not be able to participate. This study aims to gather important information that could guide future research and help improve treatments for mFND.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals diagnosed with Motor Functional Neurological Disorder (mFND)
- • Individuals aged 18-70 years
- • At least 1 mFND symptom during the year prior to enrollment
- Exclusion Criteria:
- • Current or past year self-injurious behavior
- • Current suicidality (PHQ-9 question 9 rated as 1 or above)
- • Current or past year psychosis
- • Pending litigation or current application for long term disability
- • Active substance or alcohol use disorders (dependence), at the discretion of the investigator if they preclude participation in the study
- • Serious illness requiring systemic treatment or hospitalization; the participant either completes therapy or is clinically stable on therapy, for at least 30 days prior to study entry
- • Inability to fill out the self-report surveys
- • Inability or unwillingness to participate in NBT and assigned homework
- • Currently enrolled in NBT aimed at mFND
About Rhode Island Hospital
Rhode Island Hospital, a leading academic medical center and a key component of the Lifespan health system, is committed to advancing medical research and improving patient care through innovative clinical trials. As a principal teaching hospital for The Warren Alpert Medical School of Brown University, it integrates cutting-edge research with high-quality clinical services. The hospital's extensive clinical trial program spans various fields, including oncology, cardiology, neurology, and more, aiming to enhance treatment options and patient outcomes. By fostering collaboration among researchers, clinicians, and patients, Rhode Island Hospital plays a pivotal role in translating scientific discoveries into effective therapies and improving healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Providence, Rhode Island, United States
Patients applied
Trial Officials
W. Curt LaFrance Jr, MD, MPH
Principal Investigator
Brown University Health
Emily Weisbach, MD
Study Chair
Brown University Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported